FAQ

odanacatib

Known as: (2S)-N-(1-Cyanocyclopropyl)-4-fluoro-4-methyl-2-(((1S)-2,2,2-trifluoro-1-(4'-(methylsulfonyl)(1,1'-biphenyl)-4-yl)ethyl)amino)pentanamide 
An inhibitor of cathepsin K with potential anti-osteoporotic activity. Odanacatib selectively binds to and inhibits the activity of cathepsin K… (More)
National Institutes of Health

Topic mentions per year

Topic mentions per year

2008-2018
010203020082018

Related topics

Related topics

5 relations

Broader (1)

Biphenyl Compounds
Bone Resorption InhibitionCathepsins

Narrower (2)

L-1037536MK-0822

Related mentions per year

Related mentions per year

1937-2018
19401960198020002020
odanacatib
Cathepsins
Bone Resorption Inhibition
Biphenyl Compounds
MK-0822
L-1037536

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Odanacatib for the treatment of postmenopausal osteoporosis.
INTRODUCTION The market of antiosteoporosis drugs has been declining in recent years, possibly in part due to the publicity… (More)
Is this relevant?
2014
2014
Odanacatib for the treatment of postmenopausal osteoporosis: development history and design and participant characteristics of LOFT, the Long-Term Odanacatib Fracture Trial
Odanacatib is a cathepsin K inhibitor investigated for the treatment of postmenopausal osteoporosis. Phase 2 data indicate that… (More)
  • figure 1
  • table 2
  • table 3
Is this relevant?
2013
2013
Bone density, turnover, and estimated strength in postmenopausal women treated with odanacatib: a randomized trial.
CONTEXT Odanacatib, a cathepsin K inhibitor, increases spine and hip areal bone mineral density (BMD) in postmenopausal women… (More)
  • table 1
  • figure 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2012
Highly Cited
2012
Odanacatib treatment increases hip bone mass and cortical thickness by preserving endocortical bone formation and stimulating periosteal bone formation in the ovariectomized adult rhesus monkey.
Odanacatib (ODN) is a selective and reversible inhibitor of cathepsin K (CatK). Previously, ODN was shown to increase bone… (More)
Is this relevant?
Highly Cited
2011
Highly Cited
2011
Odanacatib in the treatment of postmenopausal women with low bone mineral density: three-year continued therapy and resolution of effect.
The selective cathepsin K inhibitor odanacatib (ODN) progressively increased bone mineral density (BMD) and decreased bone… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2011
2011
The effects of the cathepsin K inhibitor odanacatib on osteoclastic bone resorption and vesicular trafficking.
Odanacatib (ODN) is a selective, potent and reversible inhibitor of cathepsin K (CatK) that inhibits bone loss in postmenopausal… (More)
Is this relevant?
Highly Cited
2010
Highly Cited
2010
Odanacatib, a cathepsin-K inhibitor for osteoporosis: a two-year study in postmenopausal women with low bone density.
Cathepsin K, a cysteine protease expressed in osteoclasts, degrades type 1 collagen. Odanacatib selectively and reversibly… (More)
Is this relevant?
2010
2010
The cathepsin K inhibitor odanacatib suppresses bone resorption in women with breast cancer and established bone metastases: results of a 4-week, double-blind, randomized, controlled trial.
BACKGROUND Metastatic bone disease (MBD) is a frequent complication in patients with breast cancer and is associated with… (More)
Is this relevant?
2009
2009
Formulation and stability of itraconazole and odanacatib nanoparticles: governing physical parameters.
The successful formulation of itraconazole and odanacatib into nanoparticle form with diameters of 145 and 350 nm, respectively… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • table 1
Is this relevant?
Highly Cited
2008
Highly Cited
2008
The discovery of odanacatib (MK-0822), a selective inhibitor of cathepsin K.
Odanacatib is a potent, selective, and neutral cathepsin K inhibitor which was developed to address the metabolic liabilities of… (More)
Is this relevant?